CONTACTS 

SUBJECTS
Thermodox IBC Treatment with Hyperthermia  Pase I/II Study Clinical

2303 -
2303 -    ..
2304 - Summary/Objective
2305 -
230501 - Follow up ref SDS 6 0000. ref SDS 5 0000.
230502 -
230503 -
230504 -
230506 -  ..
2306 -
2307 -
2308 - Progress
2309 -
230901 - Millie received ref DRT 1 0001 from Gwen transmitting notice of
230902 - complementary treatment for hyperthermia, and announcing a new trial.
230903 - This follows up Gwen's letter on 090204 submitting a list of
230904 - propspective treatments for managing Millie's cancer as a chronic
230905 - disease. ref SDS 3 7P9O
230907 -  ..
230908 - Background working with Gwen through her practice of "Beyond the 2nd
230909 - Opinion," is listed on 090205. ref SDS 5 KI5I
230910 -
230911 -    1.  Subject:  Thermodox IBC Treatment with Hyperthermia
230912 -        Date: Tue, 17 Feb 2009 19:38:22 -0800
230919 -         ..
230920 -    2.  I ran into this article (appended below) and thought you might
230921 -        be interested...
230923 -         ..
230924 -    3.  Also, I will be sending out statements in the first week of
230925 -        March.  I would like to send yours (to show your zero balance).
230926 -        Could you send me an address to mail it to?  Thanks!
230928 -         ..
230929 -    4.  I hope you current regimen is working well!
230930 -
230935 -
230936 -
230938 -  ..
230939 - Thermodox with Hyperthermia for IBC Clinical Trial Announced Celsion
230940 -
230941 -
230942 -    1.  Medical News Today
230943 -
230944 -        Celsion Commences Pivotal Phase I/II Study Of ThermoDox(R) In
230945 -        The Treatment Of Recurrent Chest Wall Breast Cancer
230947 -               ..
230948 -              http://www.medicalnewstoday.com/articles/138775.php
230950 -         ..
230951 -    2.  Date:  12 Feb 2009
230953 -         ..
230954 -    3.  Chest Wall Breast Cancer
230956 -         ..
230957 -    4.  Celsion Corporation (NASDAQ:  CLSN), an oncology company
230958 -        dedicated to the development and commercialization of therapies
230959 -        for difficult-to-treat cancers, announced today that it has
230960 -        initiated a pivotal Phase I/II study of ThermoDox in
230961 -        combination with hyperthermia, or heat, to treat recurrent
230962 -        chest wall breast cancer, a disease with a very poor patient
230963 -        prognosis and limited treatment options.
230964 -
230965 -            [On 090310 0351 Millie's letter submits agenda to medical
230966 -            team for meeting UCSF to evaluate response to treatment
230967 -            with radiation and hyperthermia, and cites evident
230968 -            worsening IBC conditions; issue of discussion for meeting
230969 -            on 090312 is requirements for adjusting treatment plan.
230970 -            ref SDS 7 TH5I
230972 -             ..
230973 -            [On 090312 0800 UCSF reports examination after 3 weeks of
230974 -            treatment with radiation and hyperthermia shows strong
230975 -            response to treatment, and says no adjustments to treatment
230976 -            are required, and so proposes ending treatment on schedule
230977 -            originally set for 090317. ref SDS 8 8P7G
230979 -         ..
230980 -    5.  The open-label, dose-escalating pivotal trial has been designed
230981 -        to measure durable local complete response at the tumor site.
230982 -        Celsion expects to enroll approximately 100 patients across the
230983 -        United States and to complete the study by the first half of
230984 -        2010. Study locations include the Florida Cancer Institute in
230985 -        Hudson, FL led by Principal Investigator Arthur Maztkowitz, MD,
230986 -        New York University Hospital in New York, NY led by Silvia
230987 -        Formenti, MD, and the Cancer Treatment Center of America in
230988 -        Tulsa, OK led by Petra Ketterl, MD. Additional information on
230989 -        the study may be found at http://www.clinicaltrials.gov.
230991 -         ..
230992 -    6.  Michael H. Tardugno, Celsion's President and Chief Executive
230993 -        Officer, commented "We are pleased to update our partners,
230994 -        particularly our shareholders, on the significant progress that
230995 -        has been made on our recurrent chest wall cancer program just
230996 -        three months after submitting our final protocol to the FDA.
230997 -        The clinical staff has brought us one step closer to delivering
230998 -        on the potential of ThermoDox to a cancer population that is
230999 -        truly in need of effective treatment options, given the
231000 -        debilitating nature of this disease, and we are extremely proud
231001 -        of their hard work and commitment to this initiative."
231003 -         ..
231004 -    7.  "Recurrent cancer at the chest wall can affect a significant
231005 -        number of breast cancer patients who have had a mastectomy",
231006 -        noted Dr. Nicholas Borys, Celsion's VP and Chief Medical
231007 -        Officer. "With no current standard of care, women with this
231008 -        type of recurrence often cannot be adequately treated with
231009 -        surgery, radiation, or existing chemotherapy. We believe that
231010 -        the DIGNITY study will demonstrate that ThermoDox in
231011 -        combination with hyperthermia will provide local tumor control
231012 -        and improve quality of life."
231014 -         ..
231015 -    8.  About Recurrent Chest Wall Cancer
231017 -         ..
231018 -        Depending on risk factors, up to 40% of women with mastectomies
231019 -        may experience recurrent chest wall cancer (RCW).  The disease
231020 -        is generally defined as the recurrence of tumor to the area of
231021 -        the initial definitive treatment such as mastectomy.  There are
231022 -        a significant number of women diagnosed with RCW who frequently
231023 -        cannot be treated with further surgical resection, radiation or
231024 -        existing chemotherapy because they have exhausted available
231025 -        treatment options.
231027 -         ..
231028 -    9.  About ThermoDox®
231029 -
231030 -        ThermoDox® is Celsion's proprietary heat-sensitive liposomal
231031 -        encapsulation of doxorubicin, an approved and frequently used
231032 -        anti-cancer drug used in the treatment of various cancers.
231033 -        Localized heat (at 40-42 degrees Celsius and above) releases
231034 -        the entrapped doxorubicin from the liposome. This delivery
231035 -        technology enables high concentrations of doxorubicin to be
231036 -        deposited preferentially in a targeted tumor.
231038 -         ..
231039 -   10.  About Celsion
231040 -
231041 -        Celsion is dedicated to the development and commercialization
231042 -        of oncology drugs including tumor-targeting treatments using
231043 -        focused heat energy in combination with heat-activated drug
231044 -        delivery systems. Celsion has research, license or
231045 -        commercialization agreements with leading institutions such as
231046 -        the National Institutes of Health, Duke University Medical
231047 -        Center, University of Hong Kong, Cleveland Clinic, North Shore
231048 -        Long Island Jewish Health System.
231050 -         ..
231051 -   11.  For more information on Celsion, visit our website:
231052 -
231053 -              http://www.celsion.com.
231055 -         ..
231056 -   12.  Celsion wishes to inform readers that forward-looking
231057 -        statements in this release are made pursuant to the "safe
231058 -        harbor" provisions of the Private Securities Litigation Reform
231059 -        Act of 1995. Readers are cautioned that such forward-looking
231060 -        statements involve risks and uncertainties including, without
231061 -        limitation, unforeseen changes in the course of research and
231062 -        development activities and in clinical trials by others;
231063 -        possible acquisitions of other technologies, assets or
231064 -        businesses; possible actions by customers, suppliers,
231065 -        competitors, regulatory authorities; and other risks detailed
231066 -        from time to time in the Company's periodic reports filed with
231067 -        the Securities and Exchange Commission.
231068 -
231069 -
231070 -
231071 -
231072 -
231073 -
231074 -
231075 -
231076 -
231077 -
231078 -
231079 -
231080 -
231081 -
231082 -
2311 -